TNDM240719P42500
- 0.09
- 0.000.00%
Tandem Diabetes Care Newsroom
Tandem Diabetes Care to Announce Second Quarter 2024 Financial Results on August 1, 2024
PDF VersionSAN DIEGO--(BUSINESS WIRE)--Jul. 11, 2024--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2024
Glaukos Cut as Citi Reviews U.S. MedTechs
Citi Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $57
Citi analyst Joanne Wuensch maintains $Tandem Diabetes Care(TNDM.US)$ with a buy rating, and maintains the target price at $57.According to TipRanks data, the analyst has a success rate of 60.7% and
Understanding Tandem Diabetes Care: Joanne Wuensch's Investment Perspective
Corning Increases Sales Forecast, Joins Morphic Holding, Lucid Group And Other Big Stocks Moving Higher On Monday
U.S. stocks were higher, with the Dow Jones index surging around 200 points on Monday.Shares of Corning Incorporated (NYSE:GLW) rose sharply during Monday's session after the company increased its sec
Stifel Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $60
Stifel analyst Mathew Blackman maintains $Tandem Diabetes Care(TNDM.US)$ with a buy rating, and maintains the target price at $60.According to TipRanks data, the analyst has a success rate of 47.9% an
Stifel Nicolaus Keeps Their Buy Rating on Tandem Diabetes Care (TNDM)
Does Tandem Diabetes Care (NASDAQ:TNDM) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' So it might be obvious
Wells Fargo Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $50
Wells Fargo analyst Larry Biegelsen maintains $Tandem Diabetes Care(TNDM.US)$ with a buy rating, and maintains the target price at $50.According to TipRanks data, the analyst has a success rate of 58.
Is weight loss medicine or stock market bomb? Eli Lilly and Co's new drug tirzepatide caused a sharp drop in sleep device stocks.
The recent clinical trial results of the new weight loss drug tirzepatide have not only caused a sensation in the medical community, but also stirred up waves in the stock market.
Tandem Diabetes, DexCom See Weakness Following ADA Conference
Lake Street Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $75
Lake Street analyst Brooks O'Neil maintains $Tandem Diabetes Care(TNDM.US)$ with a buy rating, and maintains the target price at $75.According to TipRanks data, the analyst has a success rate of 43.9%
TD Cowen Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $45
TD Cowen analyst Josh Jennings maintains $Tandem Diabetes Care(TNDM.US)$ with a buy rating, and maintains the target price at $45.According to TipRanks data, the analyst has a success rate of 50.8% an
Tandem Mobi Improves Quality of Life for People Living With Type 1 Diabetes in New Data Shared at American Diabetes Association Scientific Sessions
PDF Version SAN DIEGO--(BUSINESS WIRE)--Jun. 22, 2024-- Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today presented new real-world insight
Tandem Diabetes Appoints Jean-Claude Kyrillos as COO
Express News | Tandem Diabetes Care Appoints Jean-Claude "JC" Kyrillos As Executive Vice President And Chief Operating Officer, Effective June 21, 2024
Tandem Diabetes Care Appoints Jean-Claude Kyrillos as Chief Operating Officer
PDF Version SAN DIEGO--(BUSINESS WIRE)--Jun. 20, 2024-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Jea
Express News | Tandem Diabetes Care - Agreement Incorporates Integration of Co's Sigi Insulin Pump With Dexcom’s G7 Cgm Device, Extends Term for Period of 5 Years
Express News | Tandem Diabetes Care- on May 22, Co, Dexcom Entered Amended & Restated Development Agreement to Original Development Agreement, Dated Nov 20, 2020
Tandem Diabetes Care to Present New Early User Insights on the Tandem Mobi System at the American Diabetes Association's 84th Scientific Sessions
PDF Version SAN DIEGO--(BUSINESS WIRE)--Jun. 18, 2024-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced its schedule of presen